OTC Markets OTCQB - Delayed Quote USD

Elite Pharmaceuticals, Inc. (ELTP)

0.4480

+0.0070

+(1.59%)

As of 9:38:09 AM EDT. Market Open.

Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets

Northvale, New Jersey--(Newsfile Corp. - April 30, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Percocet® (oxycodone hydrochloride and acetaminophen tablets, USP CII) 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Oxycodone HCl and acetaminophen is indicated for the relief of moderate to moderately severe pain.IQVIA report

Newsfile 14 days ago

ELTP
+1.59%
Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line

Northvale, New Jersey--(Newsfile Corp. - March 3, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today the shipment of its first lot of finished product from its new FDA-approved expanded campus. The new facility, located at 144 Ludlow Avenue in Northvale, New Jersey, includes packaging, inventory and warehouse space. The new packaging line utilizes the latest technology, capable of pro

Newsfile 2 months ago

ELTP
+1.59%
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information

Conference Call Scheduled for Friday, February 14 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - February 13, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended December 31, 2024, which is the third quarter of the Company's fiscal year ending on March 31, 2025 ("Third Quarter").Consolidated revenu

Newsfile 2 months ago

ELTP
+1.59%
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025

Financials for the Third Quarter of Fiscal Year 2025 Ended December 31, 2024 will be released on Thursday, February 13, 2025 Northvale, New Jersey--(Newsfile Corp. - February 10, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2025 fiscal year will be released on Thursday, February 13, 2025. Elite's management will host a live confere

Newsfile 3 months ago

ELTP
+1.59%
Elite Pharmaceuticals Launches Generic Vyvanse for ADHD Market

Elite Pharmaceuticals ( (ELTP) ) has issued an update. Elite Pharmaceuticals announced the launch of its generic version of Vyvanse® (Lisdexamfetamine Disylate) in various strengths, targeting the ADHD treatment market. The product, which is marketed under the Elite Laboratories, Inc. label, is expected to capture a portion of the $4.3 billion annual sales reported by IQVIA for the original product, potentially enhancing Elite’s market presence in the generic pharmaceutical industry. More about

TipRanks 4 months ago

ELTP
+1.59%
Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)

Northvale, New Jersey--(Newsfile Corp. - December 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Vyvanse® (Lisdexamfetamine Disylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This product .

Newsfile 4 months ago

ELTP
+1.59%
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets

Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Norco® (hydrocodone bitartrate and acetaminophen tablets, USP CII) 2.5mg/325mg, 5mg/325mg, 7.5mg/325mg and 10mg/325mg tablets. Hydrocodone and acetaminophen is indicated for the management of pain severe enough to require an o

Newsfile 5 months ago

ELTP
+1.59%
Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse

Northvale, New Jersey--(Newsfile Corp. - November 18, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Vyvanse® (Lisdexamfetamine Dimesylate) with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50

Newsfile 5 months ago

ELTP
+1.59%
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information

Conference Call Scheduled for Friday, November 15 at 11:30 AM EST Northvale, New Jersey--(Newsfile Corp. - November 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended September 30, 2024, which is the second quarter of the Company's fiscal year ending on March 31, 2025 ("Second Quarter").Consolidated rev

Newsfile 5 months ago

ELTP
+1.59%
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024

Financials for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 will be released on Thursday, November 14, 2024 Northvale, New Jersey--(Newsfile Corp. - November 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the second quarter financial results of the 2025 fiscal year will be released on Thursday, November 14, 2024. Elite's management will host a live confe

Newsfile 6 months ago

ELTP
+1.59%
Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health

Northvale, New Jersey--(Newsfile Corp. - October 10, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced the Israeli Ministry of Health approval for Elite's generic version of Adderall®, an immediate-release mixed salt of a single entity Amphetamine product (Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate) with strengths of 10 mg, 20

Newsfile 6 months ago

ELTP
+1.59%
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets

Northvale, New Jersey--(Newsfile Corp. - October 7, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Tylenol® with Codeine (acetaminophen and codeine phosphate) 300mg/15mg, 300mg/30mg, and 300mg/60mg tablets.Acetaminophen and codeine phosphate tablets are indicated for the management of mild to moderate pain, where treatment w

Newsfile 7 months ago

ELTP
+1.59%
Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium

Northvale, New Jersey--(Newsfile Corp. - August 27, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic methotrexate sodium 2.5 mg tablets. Methotrexate sodium tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regim

Newsfile 8 months ago

ELTP
+1.59%
Elite Pharmaceuticals (ELTP) Posts Breakeven Q1 Earnings

Strength in Elite Pharmaceuticals' (ELTP) Manufacturing fees drive its fiscal first-quarter performance.

Zacks 8 months ago

ELTP
+1.59%
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information

Conference Call Scheduled for Thursday, August 15 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - August 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended June 30, 2024, which is the first quarter of the Company's fiscal year ending on March 31, 2025 ("First Quarter").Consolidated revenues for

Newsfile 8 months ago

ELTP
+1.59%
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024

Financials for First Quarter of Fiscal Year 2025 Ended June 30, 2024 will be released on August 14, 2024 Northvale, New Jersey--(Newsfile Corp. - August 9, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2025 fiscal year will be released on Wednesday, August 14, 2024. Elite's management will host a live conference call on ...

Newsfile 8 months ago

ELTP
+1.59%
Zacks Initiates Coverage of Elite Pharmaceuticals With Outperform Recommendation

Discover why Zacks rates Elite Pharmaceuticals as "Outperform", being the first on Wall Street to initiate coverage on the stock. Explore ELTP's strategic partnerships, financial health, and robust product pipeline.

Zacks 9 months ago

ELTP
+1.59%
Elite Pharmaceuticals' (ELTP) FY24 Earnings Up, Gross Margin Down

Elite Pharmaceuticals' (ELTP) overall top line benefits from revenue growth in Manufacturing fees.

Zacks 10 months ago

ELTP
+1.59%
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information

Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDT Northvale, New Jersey--(Newsfile Corp. - July 1, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2024 ("Fiscal 2024").Consolidated revenues for Fiscal 2024 were $56.6 million, an increase of $22.4 million or approximately 65% as compared to the comparable period of the prior fiscal y

Newsfile 10 months ago

ELTP
+1.59%
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2024 Financial Results on July 2, 2024

Financials for Fiscal Year 2024 Ended March 31, 2024 will be released on July 1, 2024 Northvale, New Jersey--(Newsfile Corp. - June 26, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it would release its 2024 fiscal year-end financial results on Monday, July 1, 2024. Elite's management will host a live conference call on Tuesday, July 2nd, at 11:30 AM EDT ...

Newsfile 10 months ago

ELTP
+1.59%

Performance Overview

Return	ELTP	S&P 500 (^GSPC)
YTD	-17.04%	-0.01%
1-Year	+220.00%	+10.80%
3-Year	+1,020.00%	+46.16%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Elite Pharmaceuticals, Inc. (ELTP)

Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets

Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line

Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025

Elite Pharmaceuticals Launches Generic Vyvanse for ADHD Market

Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)

Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets

Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024

Elite Pharmaceuticals' Generic Adderall(R) Receives Marketing Approval from the Israeli Ministry of Health

Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Codeine Phosphate Tablets

Elite Pharmaceuticals Announces Commercial Launch of Generic Methotrexate Sodium

Elite Pharmaceuticals (ELTP) Posts Breakeven Q1 Earnings

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2025 Ended June 30, 2024 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024

Zacks Initiates Coverage of Elite Pharmaceuticals With Outperform Recommendation

Elite Pharmaceuticals' (ELTP) FY24 Earnings Up, Gross Margin Down

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2024 Financial Results on July 2, 2024

Performance Overview